By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Takeda Pharmaceutical and Sage Bionetworks announced on Thursday a collaboration to identify drug targets for central nervous system diseases.

Under the agreement, Takeda, based in Osaka, Japan, will pay Sage $3.6 million in research funding and fees. Sage will develop a predictive model and identify key regulatory genes and predictive biomarkers in patients with CNS diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.